BioSpace News Archive

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, releases statements from select key members of its technical and scientific teams

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) is pleased to announce that world renowned inflammasome researchers from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Translational Research.

Eyedea Medical, a Baltimore-based medtech startup working to alleviate the burden of corneal blindness through innovative solutions in corneal transplantation and eye banking, has been awarded a $1,000,000 Phase II Small Business Innovation Research grant from the National Science Foundation.

Cartography Biosciences announced the appointment of Chester Wong as Vice President, Head of Business Development.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, provided a corporate update for shareholders.

WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today launched a new Neurostatus-eEDSS system.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile, consistent with what was seen earlier in the double-blind period (DBP) of the clinical trials.

IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report.

Kiromic BioPharma, Inc. announces that Institutional Shareholder Services and Glass Lewis & Co., two leading independent proxy advisory firms, have issued recommendations that Kiromic stockholders vote FOR all three proposals at the Company’s Special Meeting of Stockholders being held March 7, 2023.

Abivax announces the availability of a second amendment to its 2022 Universal Registration Document filed with the French Autorité des marchés financiers on April 28, 2022 under number D.22-0372 and of a listing prospectus approved by the AMF under number 23-052 on February 23, 2023, in the context of its reserved capital increase of EUR 130M.